Last Updated : November 19, 2024
Details
FilesGeneric Name:
bimekizumab
Project Status:
Active
Therapeutic Area:
Hidradenitis suppurative
Manufacturer:
UCB Canada Inc.
Call for patient/clinician input open:
Brand Name:
Bimzelx
Project Line:
Reimbursement Review
Project Number:
SR0856-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with moderate to severe hidradenitis suppurativa who have inadequate response to conventional systemic therapy.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
For the treatment of adult
patients with moderate to severe hidradenitis suppurativa
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | September 06, 2024 |
|---|---|
| Call for patient/clinician input closed | November 04, 2024 |
| Submission received | October 18, 2024 |
| Submission accepted | November 01, 2024 |
| Review initiated | November 04, 2024 |
| Draft CADTH review report(s) provided to sponsor for comment | January 31, 2025 |
| Deadline for sponsors comments | February 11, 2025 |
| CADTH review report(s) and responses to comments provided to sponsor | March 13, 2025 |
| Expert committee meeting (initial) | March 26, 2025 |
| Draft recommendation issued to sponsor | April 07, 2025 To April 09, 2025 |
| Draft recommendation posted for stakeholder feedback | April 17, 2025 |
| End of feedback period | May 05, 2025 |
Files
Last Updated : November 19, 2024